Min, Chang-Ki

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 392

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 291

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 119

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Mateos, M.-V., Sonneveld, P., Hungria, V. T. M., Nooka, A. K., Estell, J., Barreto, W. G., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 10

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

Park, J., Park, E., Jung, C.-K., Kang, S.-W., Kim, B. G., Jung, Y., Kim, T. H., Lim, J.-Y., Lee, S.-E., Min, C.-K., et al. (2016) · BMC Cancer

Ubiquitin and proteasome pathwaysMultiple Myeloma Research and Treatments

Cited by 9

Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., et al. (2024) · Cancer Research

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 6